Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833320 · ClinicalTrials.gov registry record · Phase 1
Propranolol Treatment for Postoperative Chylothorax
A Phase 1 study of Congenital Heart Disease and Open Heart Surgery, sponsored by June Wu.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06833320 is a Phase 1 study of Congenital Heart Disease and Open Heart Surgery that is actively recruiting participants, run by June Wu. The registered enrollment target is 50 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06833320, a Phase 1 study of Congenital Heart Disease and Open Heart Surgery, is actively recruiting participants, sponsored by June Wu.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Postoperative chylothorax is a serious complication after open heart surgery for pediatric patients with congenital heart disease (CHD). While it was thought to be mechanical injury to the thoracic duct, recent research demonstrated that there are intrinsically abnormal lung lymphatics in CHD patients, and after open heart surgery, the fluid shifts that occur overwhelms these abnormal lung lymphatics. As a result, postoperative chylothorax occurs. Propranolol has been found to be helpful in resolving postoperative chylothorax very quickly (9 days) in a subset of postoperative chylothorax patients (60%). However, it is not known why some patients respond and some do not. The investigators hypothesize that propranolol is safe to use in this patient population, and that certain clinical factors will predict propranolol response, but more importantly, some clinical factors can be optimize to allow more patients with postoperative chylothorax to respond to and benefit from propranolol. In order to improve the understanding of how propranolol works and to maximize benefit to patients, the investigators propose to perform a prospective, randomized, double-blind clinical trial to learn how to best use propranolol in patients with postoperative chylothorax.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol Hydrochloride
Study Locations (1)
New York
- Columbia University Irving Medical Center/NewYork-Presbyterian - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2031-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06833320
The ClinicalTrials.gov registry entry for NCT06833320 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (89% lower). The listed sponsor is June Wu, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06833320 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06833320 about?
NCT06833320 is a clinical study titled "Propranolol Treatment for Postoperative Chylothorax". Postoperative chylothorax is a serious complication after open heart surgery for pediatric patients with congenital heart disease (CHD). While it was thought to be mechanical injury to the thoracic duct, recent research demonstrated that there are intrinsically abnormal lung lymphatics in CHD patien...
What is the current status of trial NCT06833320?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-09-09. Estimated completion is 2031-01-01.
What conditions does trial NCT06833320 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Open Heart Surgery, Postoperative Chylothorax, Chylothorax.
What interventions are being tested in trial NCT06833320?
The interventions under investigation include: Placebo (DRUG), Propranolol Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06833320?
This trial is sponsored by June Wu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06833320 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
RECRUITING · Phase 1
-
Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells
COMPLETED · Phase 1
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.